Equities

Avacta Group PLC

Avacta Group PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)49.00
  • Today's Change-1.00 / -2.00%
  • Shares traded1.64m
  • 1 Year change-66.44%
  • Beta1.8197
Data delayed at least 20 minutes, as of Nov 08 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics. It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

  • Revenue in GBP (TTM)22.62m
  • Net income in GBP-25.89m
  • Incorporated2003
  • Employees154.00
  • Location
    Avacta Group PLCUnit 20, Ash WayWETHERBY LS23 7FAUnited KingdomGBR
  • Phone+44 190 421 7070
  • Fax+44 844 414 0453
  • Websitehttps://avacta.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Poolbeg Pharma PLC0.00-4.38m44.10m8.00--3.54-----0.0088-0.00880.000.02490.00----0.00-29.11---30.18--------------0.00------16.11------
Futura Medical PLC8.40m-3.75m116.70m12.00--14.85--13.90-0.0126-0.01260.02720.02590.85385,710.277.20699,850.80-38.14-79.25-47.43-127.2267.70---44.68-914.373.75--0.00-------11.40--219.68--
Scancell Holdings Plc0.00-5.86m127.82m61.00---------0.0068-0.00680.00-0.00380.00----0.00-23.24-31.66-32.48-37.66-------822.37----1.21---100.00--50.91--131.54--
Faron Pharmaceuticals Oy0.00-26.22m159.08m34.00--139.07-----0.3151-0.31510.000.01090.00----0.00-130.90-213.06-443.92-963.12-----------5.990.9022-------7.71---16.05--
4Basebio PLC596.00k-9.84m163.34m--------274.06-0.7843-0.78430.0476-0.40750.05080.645310.64---83.78---97.43--69.63---1,650.67--2.53-18.441.51--88.81---48.83------
Avacta Group Plc22.62m-25.89m180.96m154.00--3.67--8.00-0.0867-0.08670.0750.13340.25554.633.15146,876.60-29.24---61.16--42.08---114.45--1.21-1.230.3875--140.83--32.54------
hVIVO PLC64.38m17.45m185.74m274.0010.824.838.992.880.02520.02520.09320.05650.9242--4.25234,974.5025.04-0.64346.68-1.29----27.10-0.7651.60--0.2530--15.6135.402,176.68--136.55--
Bioventix PLC13.61m8.10m193.13m16.0024.2116.0923.5214.191.531.532.572.301.011.572.26--59.9558.3367.2463.6293.2093.0959.5164.127.07----90.926.177.93-3.296.67-28.4016.25
Allergy Therapeutics plc53.26m-50.22m257.39m635.00--9.73--4.83-0.0266-0.02660.0170.00560.75712.214.9283,870.87-71.39-11.59-102.10-15.1552.5470.08-94.29-11.780.9281-7.930.2713---18.11-2.71-212.65--16.41--
Puretech Health PLC362.20k-63.82m377.30m90.00--1.54--1,041.69-0.2328-0.23280.00131.020.0007--0.22524,024.44-14.134.92-16.355.94-----19,222.22352.67----0.07280.00-78.68-30.64-30.47---44.10--
Oxford BioMedica plc97.28m-142.02m436.93m834.00--6.56--4.49-1.44-1.440.96420.62920.30124.094.21136,252.10-51.98-19.60-66.85-24.6836.7450.74-172.59-44.382.07-12.470.6077---36.046.04-302.20---0.6307--
Data as of Nov 08 2024. Currency figures normalised to Avacta Group PLC's reporting currency: UK Pound GBX

Institutional shareholders

27.52%Per cent of shares held by top holders
HolderShares% Held
Hargreaves Lansdown Asset Management Ltd.as of 01 Oct 202428.09m7.76%
Jarvis Investment Management Ltd.as of 01 Oct 202418.14m5.01%
Conifer Management LLCas of 28 Apr 202311.85m3.27%
Baillie Gifford & Co.as of 28 Apr 202310.12m2.80%
IG Markets Ltd.as of 01 Oct 20249.05m2.50%
HSBC Global Asset Management (UK) Ltd.as of 01 Oct 20246.63m1.83%
AXA Investment Managers UK Ltd.as of 30 Sep 20244.53m1.25%
Unicorn Asset Management Ltd.as of 01 Oct 20243.98m1.10%
Legal & General Investment Management Ltd.as of 01 Oct 20243.74m1.03%
HSBC Bank Plc (Market-Maker)as of 01 Oct 20243.53m0.98%
More ▼
Data from 30 Jun 2024 - 01 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.